Processing

Please wait...

Settings

Settings

1. RU0002605928 - THERAPEUTIC DLL4-BINDING PROTEINS

Office Russian Federation
Application Number 2012141881/10
Application Date 28.02.2011
Publication Number 0002605928
Publication Date 27.12.2016
Grant Number
Grant Date 27.12.2016
Publication Kind C2
IPC
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39
Medicinal preparations containing antigens or antibodies
395
Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
C CHEMISTRY; METALLURGY
12
BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
N
MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15
Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09
Recombinant DNA-technology
63
Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
C CHEMISTRY; METALLURGY
12
BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
N
MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
5
Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
10
Cells modified by introduction of foreign genetic material, e.g. virus-transformed cells
C CHEMISTRY; METALLURGY
12
BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
N
MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15
Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09
Recombinant DNA-technology
11
DNA or RNA fragments; Modified forms thereof
12
Genes encoding animal proteins
13
Immunoglobulins
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
P
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
35
Antineoplastic agents
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
K
PEPTIDES
16
Immunoglobulins, e.g. monoclonal or polyclonal antibodies
18
against material from animals or humans
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
P
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
37
Drugs for immunological or allergic disorders
A61K 39/395
C12N 15/63
C12N 5/10
C12N 15/13
A61P 35/00
C07K 16/18
Inventors ЛИ Инчунь (US)
ГУ Цзицзе Джеймс (US)
МОРГАН-ЛЭПП Сьюзан (US)
ЧЭНЬ Минцзю (US)
СИЕХ Чун-Мин (US)
LI Inchun (US)
GU TSzitsze Dzhejms (US)
MORGAN-LEPP Sjuzan (US)
CHEN Mintszju (US)
SIEKH CHun-Min (US)
Priority Data 61/309,494 02.03.2010 US
Title
(EN) THERAPEUTIC DLL4-BINDING PROTEINS
(RU) ТЕРАПЕВТИЧЕСКИЕ DLL4-СВЯЗЫВАЮЩИЕ БЕЛКИ
Abstract
(EN)
FIELD: medicine. SUBSTANCE: present invention relates to immunology. Antibody and its antigen-binding fragment specifically binding human delta-like ligand 4 (DLL4) are presented, characterized by sequences determining sections complementarity (CDR). Besides, there are disclosed: isolated antibody coding nucleic acid under the invention or its antigen-binding fragment; expression vector and host cell; as well as, pharmaceutical composition and application of antibody or antigen-binding fragment according to the invention in preparing a drug for reducing human DLL4 activity in an individual human. EFFECT: present invention can find further application in therapy of diseases associated with Notch signaling. 29 cl, 30 tbl, 13 ex

(RU)
Данное изобретение относится к области иммунологии. Предложены антитело и его антигенсвязывающий фрагмент, которые специфично связывают дельта-подобный лиганд 4 (DLL4) человека, охарактеризованные последовательностями определяющих комплементарность участков (CDR). Кроме того, рассмотрены: выделенная нуклеиновая кислота, кодирующая антитело по изобретению или его антигенсвязывающий фрагмент; вектор экспрессии и клетка-хозяин; а также фармацевтическая композиция и применение антитела или антигенсвязывающего фрагмента по изобретению в приготовлении лекарственного средства для снижения активности DLL4 человека у субъекта-человека. Настоящее изобретение может найти дальнейшее применение в терапии заболеваний, связанных с сигнальным путем Notch. 6 н. и 23 з.п. ф-лы, 30 табл., 13 пр.